Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $42.75.
Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, May 4th. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Finally, Guggenheim lifted their target price on Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, April 6th.
Read Our Latest Report on Assembly Biosciences
Institutional Trading of Assembly Biosciences
Assembly Biosciences Stock Up 2.3%
NASDAQ ASMB opened at $30.41 on Thursday. The stock’s 50-day moving average price is $28.69 and its 200-day moving average price is $30.56. Assembly Biosciences has a 52 week low of $12.11 and a 52 week high of $39.71. The company has a market capitalization of $483.21 million, a P/E ratio of -276.43 and a beta of 1.08.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. The company had revenue of $8.21 million for the quarter, compared to the consensus estimate of $9.27 million. Assembly Biosciences had a negative return on equity of 4.70% and a negative net margin of 8.98%. Research analysts anticipate that Assembly Biosciences will post -0.93 EPS for the current year.
About Assembly Biosciences
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.
Read More
- Five stocks we like better than Assembly Biosciences
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
